Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. - Wikidata - awgldk - TriplyDB

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours.

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours.

http://www.wikidata.org/entity/Q33382682

about

The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges Arsenic trioxide overcomes rapamycin-induced feedback activation of AKT and ERK signaling to enhance the anti-tumor effects in breast cancer Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway.A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC).A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer.A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer.Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer.A hexane fraction of guava Leaves (Psidium guajava L.) induces anticancer activity by suppressing AKT/mammalian target of rapamycin/ribosomal p70 S6 kinase in human prostate cancer cells Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies Pharmacokinetic study of 3-in-1 poly(ethylene glycol)-block-poly(D, L-lactic acid) micelles carrying paclitaxel, 17-allylamino-17-demethoxygeldanamycin, and rapamycin Neurotoxicity of biologically targeted agents in pediatric cancer trials Reduced BCL2 and CCND1 mRNA expression in human cervical cancer HeLa cells treated with a combination of everolimus and paclitaxel.Mithramycin A induces apoptosis by regulating the mTOR/Mcl-1/tBid pathway in androgen-independent prostate cancer cells.A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer.The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer.A Review of mTOR Pathway Inhibitors in Gynecologic Cancer Therapeutic drug monitoring in cancer chemotherapy.Everolimus: targeted therapy on the horizon for the treatment of breast cancer.Research and innovation in the development of everolimus for oncology.The Biological Role of PI3K Pathway in Lung Cancer.Exploiting the therapeutic potential of the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies.Serum levels after everolimus-stent implantation and paclitaxel-balloon angioplasty in an infant with recurrent pulmonary vein obstruction after repaired total anomalous pulmonary venous connection.AMPK and PFKFB3 mediate glycolysis and survival in response to mitophagy during mitotic arrest.Brassinin induces apoptosis in PC-3 human prostate cancer cells through the suppression of PI3K/Akt/mTOR/S6K1 signaling cascades.Embelin inhibits growth and induces apoptosis through the suppression of Akt/mTOR/S6K1 signaling cascades.Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer.Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters.Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non-small-cell lung cancer cells.New Insights into mTOR Signal Pathways in Ovarian-Related Diseases: Polycystic Ovary Syndrome and Ovarian Cancer Active TGF-β signaling and decreased expression of PTEN separates angiosarcoma of bone from its soft tissue counterpart.Molecular alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer.Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2-Negative Metastatic Breast Cancer.

P2860

Q26851852-DC1ADE4A-9C8F-4029-B407-BEDF592CF461 Q27332151-5E78FB41-9481-4606-885C-BA0FC9486919 Q27853128-117BF46D-BA86-4E48-BE67-EB96D6111302 Q30583249-B32A2D94-8BE8-45F2-B9C2-6FA4DFF90CD4 Q33401499-14F1F794-5D88-461A-AEEA-092C880C4BAA Q33405880-93C32397-899D-4007-BEDA-D94D8A6FD2DC Q33409908-E0F7DA0F-F642-431E-B16F-C4DF6AF0AF04 Q33410691-54BB7085-F61D-408A-BF3B-DC8B46960564 Q33493174-C66958ED-C8F8-4947-8A28-3DAF37B897A6 Q33683126-3931C2C0-1D52-4DA8-811D-3C0B421A1F59 Q33787400-8F469DD3-975F-4A21-A7DA-4925831854F8 Q34048144-7D80E2F5-9043-4741-859E-5E0706A21339 Q34130665-A6CEAB74-A093-4191-9786-B8B768520775 Q35170258-6DA25A38-63B2-459E-A5A0-7C796095881F Q35638434-5CA92415-AA89-444C-B503-C64A4C4CC57B Q35765678-22AF0F36-12A2-4F7D-B099-0DBA43AA2B31 Q36072040-CF0E8916-A508-4185-A946-4C5015217DE6 Q36174463-3C60AC59-381D-4A75-9CC8-38230EDD250F Q36766221-82AC3012-16E1-438F-86B6-82B6BBBA50D6 Q36792877-23626EDB-D679-4047-AD3D-E79B0A9AD283 Q37176520-020F56B5-A678-4A7B-977D-B4ECC44F5545 Q37483253-0ED41663-EA83-40D5-B222-BFFD0ADC6382 Q37631697-C90E12E9-023C-4158-846D-BE53B5D153BA Q37668889-E74F3D5A-36E3-40C1-85A9-3CA5CF92D9B5 Q37810220-6EC0C088-4ACF-4AFB-A75C-1A757C34DCEE Q37998418-04CF8324-A283-40BD-9FB7-4AD4C3CD27AC Q38014589-1FE6030C-FB06-4BE1-902C-2FAF2B5F0272 Q38166599-E4E12B6F-325F-4914-86FB-CC90A60EFA97 Q38258712-0BE9CA0C-06A4-4C72-BB2E-43D5138DCACF Q38463876-013DDB63-F268-45A8-A700-C9FD8F4139A1 Q38839407-D02259A8-A40D-4133-AF4B-E69EBC2FCF36 Q39149824-9850435B-C96C-45E0-98C0-4CA49D53CC06 Q39298748-9930026B-B972-4C39-ACA8-575DFF3C60AF Q39520887-97803A96-3ADE-42D0-BC9D-F921AFDA4085 Q39552173-F2FFE429-4E08-4AF2-AB64-9A4DDA3D00B0 Q39552585-11287397-17C9-4B73-B387-36EB538A195B Q42144129-DD8020C7-7E7E-453C-94DE-12036265716E Q51061499-EEAD084B-C641-4187-A345-965E7FC45487 Q54377413-2B6A9C33-211D-428E-A477-316147A4E51B Q55000079-AA2118D7-621D-489A-8F7A-BF78938B109A

P2860

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours.

http://www.wikidata.org/entity/Q33382682

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Safety and pharmacokinetics of ...... mus in advanced solid tumours.

@ast

Safety and pharmacokinetics of ...... mus in advanced solid tumours.

@en

type

label

Safety and pharmacokinetics of ...... mus in advanced solid tumours.

@ast

Safety and pharmacokinetics of ...... mus in advanced solid tumours.

@en

prefLabel

Safety and pharmacokinetics of ...... mus in advanced solid tumours.

@ast

Safety and pharmacokinetics of ...... mus in advanced solid tumours.

@en

P1433

Q33382682-4C877AB9-806D-46B0-91B4-60CF24C3C2CD

P1476

Q33382682-1B7BB539-64CD-46E2-9172-AFE9939C6DD8

P2093

Q33382682-094ED241-91C1-4B40-93DB-7E152E68F6BF

Q33382682-380599D0-02AD-49BB-8665-DD8ADDC136B4

Q33382682-7C50EED9-960B-4B8C-93AF-8AE5E1E70793

Q33382682-8D6B183A-53AC-429A-BD0B-366044FA91E7

Q33382682-A40EFC8D-8E61-46AC-8A99-70013F939179

Q33382682-B5A6FE30-B43A-4480-ABDA-8AA9D7AAA61A

Q33382682-B7B31BC7-6D69-4AB2-9057-FF0BA871258F

Q33382682-BF9CBB0A-1F57-43AD-AB05-56D2F4B2710F

Q33382682-CEA03AAD-038C-45A8-8B92-C4724BD4C50B

P2860

Q33382682-00C6F313-0B9F-4DE7-B70F-279998353914

Q33382682-0552B49C-9E81-4717-A46F-C210EAC995C6

Q33382682-0CA5A6E4-C6B3-4FAD-9239-9076372224FB

Q33382682-1890BC3A-D1FB-49B8-A43E-25B5C3433C4B

Q33382682-1A5DAEC5-AA9C-4C5D-9550-56151851E849

Q33382682-2E182D6A-E0FB-4B9C-8515-2A988B651E88

Q33382682-2F8C706C-0C81-4833-B772-DB4099B6FB3C

Q33382682-3428CA09-B2A7-4170-8AFE-63A734409D14

Q33382682-3595C77B-4565-47A4-A921-88C7C0747C6B

Q33382682-35EC595B-4A8C-41C3-B80D-3DDFB8A84F61

P2888

Q33382682-B7E398C0-E11B-4DA2-864C-05AD268D7538

P304

Q33382682-85CAE5BF-ACF6-4D59-9789-6D1C41F1913A

P31

Q33382682-6428B84F-6CE2-4E6D-B30F-5EFE32762091

P356

Q33382682-63588ABC-8505-487F-951E-2F344DAB39A7

P407

Q33382682-867E4FBE-E68B-454A-BCBC-7A294CE07578

P433

Q33382682-4058A72D-E10B-41A2-B502-5FC73A1F353B

P478

Q33382682-0116AB9B-121B-4DCC-B147-7A4A0412FCEE

P50

Q33382682-CE03F1AB-AE33-46AF-95A1-105515330FA7

P577

Q33382682-7C75B29B-982D-4EAA-9505-E3F115C09D7C

P5875

Q33382682-4FD07FA2-A798-4C87-87EB-374F2DBFD764

P6179

Q33382682-CEC62242-D74C-40D1-84DC-E37878CDA4C0

P698

Q33382682-C1C8B2A6-1575-49AA-9BED-B7C25598E012

P932

Q33382682-87129F02-F22B-485D-92FE-EE4E7ED795A8

P356

P1433

British Journal of Cancer

P1476

Safety and pharmacokinetics of ...... imus in advanced solid tumours

@en

P2093

C Dutreix

http://www.w3.org/2001/XMLSchema#string

D Berton Rigaud

http://www.w3.org/2001/XMLSchema#string

D Bootle

http://www.w3.org/2001/XMLSchema#string

E Bourbouloux

http://www.w3.org/2001/XMLSchema#string

E Raymond

http://www.w3.org/2001/XMLSchema#string

F Calvo

http://www.w3.org/2001/XMLSchema#string

M Campone

http://www.w3.org/2001/XMLSchema#string

N Shand

http://www.w3.org/2001/XMLSchema#string

U Zoellner

http://www.w3.org/2001/XMLSchema#string

P2860

High frequency of mutations of the PIK3CA gene in human cancers

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

Current development of mTOR inhibitors as anticancer agents

Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel.

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.

Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.

Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapy.

Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer.

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.

Sirolimus-associated pulmonary toxicity.

P2888

P304

315-321

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6604851

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-01-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23762232

http://www.w3.org/2001/XMLSchema#string

P6179

1013560743

http://www.w3.org/2001/XMLSchema#string

P698

19127256

http://www.w3.org/2001/XMLSchema#string

P932

2634724

http://www.w3.org/2001/XMLSchema#string